Cost-effectiveness Analysis of First-line Treatment of Large-volume,Hormone-sensitive Metastatic Prostate Cancer with Rezvilutamide
OBJECTIVE To analyze the economics of first-line androgen deprivation therapy combined with rezvilutamide and bicalutamide in the treatment of large-volume,metastatic,hormone-sensitive prostate cancer.METHODS From the point of view of China's health system,a three-state partition survival model of progression-free survival,disease progression and death was constructed based on CHART data and Excel 2019 for cost-utility analysis.The cycle time of the model was 4 weeks,the duration of study was lifetime,and the discount rate of cost and effect was set at 5％.The main outputs were total cost,quality-adjusted life years(QALYs)and incremental cost-effectiveness ratio(ICER).Single factor sensitivity analysis and probability sensitivity analysis were carried out for the important parameters in the model.RESULTS Baseline analysis:compared with the bicalutamide regimen,the rezvilutamide regimen resulted in an increase of 2.293 QALYs with a concurrent cost increase of 519 025.32 Yuan and an ICER of 226 379.14 yuan per QALY.Univariate sensitivity analysis showed that progression-free survival status utility,cost of rezvilutamide,and discount rate had significant effects on ICER.The probability sensitivity analysis showed that when the willing to pay was 3 times the gross domestic product per 2021 of China,the probability was 73.8％.CONCLUSION The first-line treatment of high-volume,metastatic,hormone-sensitive prostate cancer with the rezvilutamide regimen is economical at a 2021 of China's gross domestic product per capita threshold.
rezvilutamidebicalutamidehormone-sensitive prostate cancerpartitioned survival modelquality-adjusted life yearsincermental cost-effectiveness ratio
万方数据
维普
